Fang Yan
Last active: 4/11/2016

Epidermal growth factor receptor inhibits colitis-associated cancer in mice.

Dubé PE, Yan F, Punit S, Girish N, McElroy SJ, Washington MK, Polk DB
J Clin Invest. 2012 122 (8): 2780-92

PMID: 22772467 · PMCID: PMC3408743 · DOI:10.1172/JCI62888

Inflammatory bowel disease (IBD) is a chronic illness caused by complex interactions between genetic and environmental factors that propagate inflammation and damage to the gastrointestinal epithelium. This state of chronic inflammation increases the risk for development of colitis-associated cancer in IBD patients. Thus, the development of targeted therapeutics that can disrupt the cycle of inflammation and epithelial injury is highly attractive. However, such biological therapies, including those targeting epidermal growth factor receptor pathways, pose a risk of increasing cancer rates. Using two mouse models of colitis-associated cancer, we found that epidermal growth factor receptor inactivation accelerated the incidence and progression of colorectal tumors. By modulating inflammation and epithelial regeneration, epidermal growth factor receptor optimized the response to chronic inflammation and limited subsequent tumorigenesis. These findings provide important insights into the pathogenesis of colitis-associated cancer and suggest that epidermal growth factor-based therapies for IBD may reduce long-term cancer risk.

MeSH Terms (19)

Animals Colitis Colon Colorectal Neoplasms Cytokines Disease Models, Animal Disease Progression ErbB Receptors Gene Expression Profiling Humans Inflammatory Bowel Diseases Interleukin-10 Mice Mice, Knockout Mutation Proto-Oncogene Proteins B-raf Risk Factors Signal Transduction Tumor Suppressor Proteins

Connections (1)

This publication is referenced by other Labnodes entities: